Clinical Trial Detail

NCT ID NCT02664181
Title Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Decitabine + Nivolumab + Tetrahydrouridine

Age Groups: adult

No variant requirements are available.